Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward J Modestino

Showing results (31-40 of 62) with videos related to

Pageof 7
Sort By:
Current Psychopharmacology|May 21, 2020
In Search of Reward Deficiency Syndrome (RDS)-free Controls: The "Holy Grail" in Genetic Addiction Risk TestingKenneth Blum, David Baron, Lisa Lott, et al.
Acta Scientific Neurology|August 29, 2025
Is It Scientifically Possible To 'Cure" Reward Deficiency Syndrome (RDS) Via Transplice Molecular Genetic Technology?Kenneth Blum, Alireza Sharafshah, Kai -Uwe-Lewandowski, et al.
Substance Use & Misuse|December 20, 2017
A Systematic, Intensive Statistical Investigation of Data from the Comprehensive Analysis of Reported Drugs (CARD) for Compliance and Illicit Opioid Abstinence in Substance Addiction Treatment with Buprenorphine/naloxoneKenneth Blum, David Han, Edward J Modestino, et al.
Journal of Addiction Psychiatry|February 14, 2025
Complex NADASE Infusions Improve Clinical Outcome in Substance Use Disorder: Descriptive Annotation in Fifty CasesKenneth Blum, Thomas Mclaughlin, Kai Uwe Lewandrowski, et al.
Current Pharmaceutical Biotechnology|December 11, 2019
Hypodopaminergia and "Precision Behavioral Management" (PBM): It is a Generational Family AffairLyle Fried, Edward J Modestino, David Siwicki, et al.
Current Psychopharmacology|October 28, 2021
Exploration of Epigenetic State Hyperdopaminergia (Surfeit) and Genetic Trait Hypodopaminergia (Deficit) During Adolescent Brain DevelopmentKenneth Blum, Abdalla Bowirrat, Marjorie C Gondre Lewis, et al.
Frontiers in Bioscience (Elite Edition)|September 21, 2017
Genetic addiction risk score (GARS) ™, a predictor of vulnerability to opioid dependenceKenneth Blum, Amanda L C Chen, Panayotis K Thanos, et al.
Journal of the Neurological Sciences|September 9, 2022
Why haven't we solved the addiction crisis?Kenneth Blum, Abdalla Bowirrat, Luis Llanos Gomez, et al.
Journal of Personalized Medicine|February 25, 2022
Reward Deficiency Syndrome (RDS) Surprisingly Is Evolutionary and Found Everywhere: Is It "Blowin' in the Wind"?Kenneth Blum, Thomas McLaughlin, Abdalla Bowirrat, et al.
International Journal of Genomics and Data Mining|September 11, 2018
The Benefits of Genetic Addiction Risk Score (GARSKenneth Blum, Edward J Modestino, Marjorie Gondre-Lewis, et al.
Pageof 7

Showing results (31-40 of 62) with videos related to

Sort By:
Pageof 7
Current Psychopharmacology|May 21, 2020
In Search of Reward Deficiency Syndrome (RDS)-free Controls: The "Holy Grail" in Genetic Addiction Risk TestingKenneth Blum, David Baron, Lisa Lott, et al.
Acta Scientific Neurology|August 29, 2025
Is It Scientifically Possible To 'Cure" Reward Deficiency Syndrome (RDS) Via Transplice Molecular Genetic Technology?Kenneth Blum, Alireza Sharafshah, Kai -Uwe-Lewandowski, et al.
Substance Use & Misuse|December 20, 2017
A Systematic, Intensive Statistical Investigation of Data from the Comprehensive Analysis of Reported Drugs (CARD) for Compliance and Illicit Opioid Abstinence in Substance Addiction Treatment with Buprenorphine/naloxoneKenneth Blum, David Han, Edward J Modestino, et al.
Journal of Addiction Psychiatry|February 14, 2025
Complex NADASE Infusions Improve Clinical Outcome in Substance Use Disorder: Descriptive Annotation in Fifty CasesKenneth Blum, Thomas Mclaughlin, Kai Uwe Lewandrowski, et al.
Current Pharmaceutical Biotechnology|December 11, 2019
Hypodopaminergia and "Precision Behavioral Management" (PBM): It is a Generational Family AffairLyle Fried, Edward J Modestino, David Siwicki, et al.
Current Psychopharmacology|October 28, 2021
Exploration of Epigenetic State Hyperdopaminergia (Surfeit) and Genetic Trait Hypodopaminergia (Deficit) During Adolescent Brain DevelopmentKenneth Blum, Abdalla Bowirrat, Marjorie C Gondre Lewis, et al.
Frontiers in Bioscience (Elite Edition)|September 21, 2017
Genetic addiction risk score (GARS) ™, a predictor of vulnerability to opioid dependenceKenneth Blum, Amanda L C Chen, Panayotis K Thanos, et al.
Journal of the Neurological Sciences|September 9, 2022
Why haven't we solved the addiction crisis?Kenneth Blum, Abdalla Bowirrat, Luis Llanos Gomez, et al.
Journal of Personalized Medicine|February 25, 2022
Reward Deficiency Syndrome (RDS) Surprisingly Is Evolutionary and Found Everywhere: Is It "Blowin' in the Wind"?Kenneth Blum, Thomas McLaughlin, Abdalla Bowirrat, et al.
International Journal of Genomics and Data Mining|September 11, 2018
The Benefits of Genetic Addiction Risk Score (GARSKenneth Blum, Edward J Modestino, Marjorie Gondre-Lewis, et al.
Pageof 7